Abstract: The present invention relates to a composition for prevention and/or treatment of human skin alteration or disease comprising an extract of marine bacteria selected from Flavobacteriaceae, wherein the extract contains an effective amount of zeaxanthin. The present invention also relates to a method for preparing the above composition, comprising: (a) culturing marine bacteria selected from Flavobacteriaceae, more specifically, from Olleya marilimosa, in a liquid culturing medium to form pigments containing zeaxanthin; (b) separating cell mass of the marine bacteria with the pigments and the liquid culturing medium and collect the cell mass to obtain the above composition, and (c) optionally mixing the cell mass and a carrier.

Abstract: The present invention relates to a composition for prevention and/or treatment of human skin alteration or disease comprising an extract of marine bacteria selected from Flavobacteriaceae, wherein the extract contains an effective amount of zeaxanthin. The present invention also relates to a method for preparing the above composition, comprising: (a) culturing marine bacteria selected from Flavobacteriaceae, more specifically, from Olleya marilimosa, in a liquid culturing medium to form pigments containing zeaxanthin; (b) separating cell mass of the marine bacteria with the pigments and the liquid culturing medium and collect the cell mass to obtain the above composition, and (c) optionally mixing the cell mass and a carrier.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of three novel human Ron-related gene variants (Ron-V1, Ron-V2, and Ron-V3). The invention also provides a process for producing the polypeptides of the variants, as well as uses for the nucleic acid, polypeptide and antibodies to same in diagnosing human breast carcinoma, breast adenocarcinoma, cervix epidermoid carcinoma, cervix epitheloid carcinoma, colon adenocarcinoma, urinary bladder carcinoma, prostate carcinoma, esophagus epidermoid carcinoma and esophagus carcinoma.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of three novel human Ron-related gene variants (Ron-V1, Ron-V2, and Ron-V3). The invention also provides a process for producing the polypeptides of the variants, as well as uses for the nucleic acid, polypeptide and antibodies to same in diagnosing human breast carcinoma, breast adenocarcinoma, cervix epidermoid carcinoma, cervix epitheloid carcinoma, colon adenocarcinoma, urinary bladder carcinoma, prostate carcinoma, esophagus epidermoid carcinoma and esophagus carcinoma.

Abstract: A rechargeable biosensor for the quantitative determination of an analyte is disclosed. The rechargeable biosensor mainly comprises a charging circuit, a charge storage circuit, and an operation circuit. The charging circuit may be selectively electrically coupled to an external power source for receiving a voltage; the charge storage circuit is electrically coupled to the charging circuit and being rechargeable by the charging circuit when the charging circuit is electrically coupled to the external power source; the operation circuit is electrically coupled to the charge storage circuit for receiving an operation voltage from the charge storage circuit, wherein the operation circuit is adapted to measure an electrical signal derived from the analyte and output a quantitative property of the analyte.

Abstract: A bio-monitoring system used for the determination of analyte in a liquid sample, comprising (1) a meter and a test strip integrated using RFID, wherein the RFID comprises a RFID reader and a RFID tag, wherein the RFID tag is embedded in the test strip or attached to the test strip vial/container, and the RFID tag stores the calibration parameters and strip type information of the test strip; and (2) a radio transmission process system.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of three novel human Ron-related gene variants (Ron-V1, Ron-V2, and Ron-V3). The invention also provides a process for producing the polypeptides of the variants, as well as uses for the nucleic acid, polypeptide and antibodies to same in diagnosing human breast carcinoma, breast adenocarcinoma, cervix epidermoid carcinoma, cervix epitheloid carcinoma, colon adenocarcinoma, urinary bladder carcinoma, prostate carcinoma, esophagus epidermoid carcinoma and esophagus carcinoma.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of three novel human Ron-related gene variants (Ron-V1, Ron-V2, and Ron-V3). The invention also provides a process for producing the polypeptides of the variants, as well as uses for the nucleic acid, polypeptide and antibodies to same in diagnosing human breast carcinoma, breast adenocarcinoma, cervix epidermoid carcinoma, cervix epitheloid carcinoma, colon adenocarcinoma, urinary bladder carcinoma, prostate carcinoma, esophagus epidermoid carcinoma and esophagus carcinoma.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of three novel human Ron-related gene variants (Ron-V1, Ron-V2, and Ron-V3). The invention also provides a process for producing the polypeptides of the variants, as well as uses for the nucleic acid, polypeptide and antibodies to same in diagnosing human breast carcinoma, breast adenocarcinoma, cervix epidermoid carcinoma, cervix epitheloid carcinoma, colon adenocarcinoma, urinary bladder carcinoma, prostate carcinoma, esophagus epidermoid carcinoma and esophagus carcinoma.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of three novel human Ron-related gene variants (Ron-V1, Ron-V2, and Ron-V3). The invention also provides a process for producing the polypeptides of the variants, as well as uses for the nucleic acid, polypeptide and antibodies to same in diagnosing human breast carcinoma, breast adenocarcinoma, cervix epidermoid carcinoma, cervix epitheloid carcinoma, colon adenocarcinoma, urinary bladder carcinoma, prostate carcinoma, esophagus epidermoid carcinoma and esophagus carcinoma.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of one novel human PPEF-1-related gene variant (PPEF-1V). The invention also provides a process for making the polypeptides of the variant. The invention further provides a use of the nucleic acid and polypeptide sequences of the gene variant in diagnosing T-cell lymophoblastic lymphoma.

Abstract: Nucleic acid and polypeptide sequences of one novel human KIP2-related gene variant (KIP2V), and the processes for producing the same are provided. Use of the nucleic acid and polypeptide sequences of the gene variant in diagnosing cancers is also provided.

Abstract: The present invention provides an electrochemical biosensor test strip used for quantitative determination of an analyte in a liquid sample. Methods of fabricating the test strip and reagent formulas are also provided. Improvements in electrochemical test strips are required to detect the presence of a compound in a liquid mixture using a smaller sample size with increased accuracy. The present invention was developed to be user-friendly, decrease sample requirements and decrease analyzing time while increasing the reproducibility and accuracy of the electrochemical test strip.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of a novel human RPS6KA6-related gene variant (RPS6KA6V). The invention also provides a process for producing the polypeptide of the variant. The invention further provides a use of the nucleic acid and polypeptide sequences of the gene variant in diagnosing T-cell lymphoblastic lymphoma.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of two novel human GAK-related gene variants. The invention also relates to the process for producing the polypeptides of the variants. The invention further relates to the use of the nucleic acid and polypeptide sequences of the gene variants in diagnosing diseases associated with the deficiency of GAK gene, in particular, iron homeostasis impairment-related diseases or non-small cell lung cancer (NSCLC), e.g. large cell lung cancer.

Abstract: Nucleic acid and polypeptide sequences of one novel human KIP2-related gene variant (KIP2V1), and the processes for producing the same are provided. Use of the nucleic acid and polypeptide sequences of the gene variant in diagnosing diseases associated with the presence of KIP2V1, in particular prostate cancer, is also provided.

Abstract: The invention relates to a novel human PEN11B-related gene variant, and to the use of the nucleic acid of the gene variant in diagnosing diseases, in particular, lung cancer, e.g. small cell lung cancer.

Abstract: The invention relates to the nucleic acid sequences of two novel human ARL-related gene variants (ARLV1 and ARLV2) and the polypeptides encoded by ARLV1 and ARLV2. The invention also relates to the process for producing the polypeptides encoded by ARLV1 and ARLV2. The invention further relates to the use of the nucleic acid of ARLV1 and ARLV2 and the polypeptide encoded by ARLV1 and ARLV2 in diagnosing diseases associated with the deficiency of human ARLV gene, in particular large cell lung cancer or hepatocellular carcinoma.

Abstract: The invention relates to the nucleic acid of a novel human MATK-related variant (MATKV) and the polypeptides encoded thereby. The invention also provides a process for producing the polypeptide encoded by MATKV. The invention further provides the uses of the nuclei acid of MATKV and the polypeptide encoded thereby in diagnosing the disease associated with the deficiency of human MATK gene, in particular lung cancers, preferably small cell lung cancers.

Abstract: The invention relates to the nucleic acid and polypeptide sequences of two novel human GAK-related gene variants. The invention also relates to the process for producing the polypeptides of the variants. The invention further relates to the use of the nucleic acid and polypeptide sequences of the gene variants in diagnosing diseases associated with the deficiency of GAK gene, in particular, iron homeostasis impairment-related diseases or non-small cell lung cancer (NSCLC), e.g. large cell lung cancer.